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ABSTRACT
Introduction: The aim of this study was to
evaluate the cost-effectiveness of rivaroxaban
and apixaban versus enoxaparin for the
universal prophylaxis of venous
thromboembolism (VTE) and associated
long-term complications in Chinese patients
after total hip replacement (THR).
Methods: A decision model, which included
both acute VTE (represented as a decision tree)
and the long-term complications of VTE
(represented as a Markov model), was
developed to assess the economic outcomes of
the three prophylactic strategies for Chinese
patients after THR. Transition probabilities for
acute VTE were derived from two randomized
controlled studies, RECORD1 and ADVANCE3,
of patients after THR. The transition
probabilities of long-term complications after
acute VTE, utilities, and costs were derived from
the published literature and local healthcare
settings. One-way and probabilistic sensitivity
analyses (PSA) were performed to test the
uncertainty concerning the model parameters.
The quality-adjusted life years (QALYs) and
direct medical costs were reported over a
5-year horizon, and incremental
cost-effectiveness ratios (ICERs) were also
calculated.
Results: Thromboprophylaxis with apixaban
was estimated to have a higher cost (US
$178.70) and more health benefits (0.0025
QALY) than thromboprophylaxis with
enoxaparin over a 5-year time horizon, which
resulted in an ICER of US $71,244 per QALY
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gained and was more than three times the GDP
per capita of China in 2014 (US $22,140).
Owing to the higher cost and lower generated
QALYs, rivaroxaban was inferior to enoxaparin
among post-THR patients. The sensitivity
analyses confirmed these results.
Conclusions: The analysis found that apixaban
was not cost-effective and that rivaroxaban was
inferior to enoxaparin. This finding indicates
that compared with enoxaparin, the use of
apixaban for VTE prophylaxis after THR does
not represent a good value for the cost at the
acceptable threshold in China; in addition, the






Major orthopedic surgery, such as total knee
replacement (TKR) and total hip replacement
(THR), is associated with a high risk of venous
thromboembolism (VTE), which comprises
deep vein thrombosis (DVT) and pulmonary
embolism (PE) [1]. Long-term consequences
arising from VTE include recurrent VTE,
post-thrombotic syndrome (PTS), and chronic
thromboembolic pulmonary hypertension
(CTEPH), which further increase the disease
burden related to VTE [2]. One prospective
epidemiological study that included 837 Asian
patients without thromboprophylaxis and who
were undergoing elective THR, TKR, or hip
fracture surgery (HFS) from 19 centers across
Asia reported an incidence of total DVT of
41.0% (95% confidence interval [CI]
35.4–46.7), including 63.8% of patients
without symptoms [3]. Despite the availability
of current thromboprophylactic interventions,
the incidence rate of symptomatic DVT in
Chinese patients after THR is 2.40–6.49%,
which is much higher than the 0.20–0.22%
reported in Asia and the 0.26–1.30% reported
in Western countries; furthermore, the rate of
symptomatic PE in China is 0.30–0.47%, which
is higher than the 0.00–0.04% reported in Asia
and similar to the 0.14–2.00% reported in
Western countries [4]. Thus, it is critical to
improve VTE prophylaxis for patients with
THR in China.
Low molecular weight heparins (LMWH),
such as enoxaparin, are frequently used for
thromboprophylaxis in Chinese patients
undergoing THR [5]. In recent years,
rivaroxaban (Xarelto, Bayer Schering Pharma
AG) and apixaban (Eliquis, Bristol-Myers
Squibb/Pfizer EEIG), two oral factor Xa
inhibitors, were licensed for VTE prophylaxis
in China for patients undergoing THR. Pivotal
studies have found that these new oral
anticoagulants have a higher efficacy in
reducing the risk of symptomatic VTE but a
higher bleeding tendency in comparison with
enoxaparin [6]. However, owing to the rapidly
increasing healthcare demand and limited
resources in China, the use of these new oral
anticoagulants should be carefully considered
in the decision-making process by balancing the
clinical benefits and the related costs. Although
there have been several published economic
evaluations of the new oral
thromboprophylactic agents for patients
undergoing major orthopedic surgery in
different settings [7–13], these evaluations
have been mainly conducted in developed
countries.
The objective of this study was to assess the
cost-effectiveness of apixaban and rivaroxaban
versus enoxaparin for prophylaxis against VTE
in patients undergoing THR, from the
perspective of the Chinese healthcare system.
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METHODS
Economic Model Overview
A decision-analytic model was developed to
evaluate the cost-effectiveness of apixaban and
rivaroxaban versus enoxaparin for the
prevention of VTE in patients undergoing
THR. The model included a 180-day
decision-tree module for the acute phase
(Fig. 1a) and a Markov process module for
complications in the long-term phase (Fig. 1b),
which was similar to the approach adopted in
previously published studies [8–10]. Because
only a paucity of information is available on
the long-term clinical course of the disease and
only recent events were considered
pragmatically from a decision-maker’s
perspective, a 5-year time horizon was used in
the long-term phase [14]. At the beginning of
the decision tree, the patients would receive one
of the three following agents for the
Fig. 1 Structure of the decision model with the decision
tree for the acute phase (a) and the Markov model for
long-term complications (b). DVT deep vein thrombosis,
PE pulmonary embolism, VTE venous thromboembolism,
CTEPH chronic thromboembolic pulmonary hypertension,
PTS post-thrombotic syndrome, THR total hip replacement,
M Markov model, D decision tree
468 Adv Ther (2017) 34:466–480
prophylaxis of VTE after THR: enoxaparin,
rivaroxaban, or apixaban. Upon receiving
prophylaxis, the risk of incurring a
prophylaxis-related major bleeding event,
which might lead to death or no sequelae, was
considered.
Surgery-related VTE, including distal DVT,
proximal DVT, and PE, may develop in patients
treated with THR. It was assumed that only
symptomatic VTEs would be treated, whereas
asymptomatic VTEs would remain untreated
and would not incur costs or decreased utility.
Distal DVTs were assumed to have a risk of
propagating to the proximal veins [8], whereas
there was a risk of proximal DVTs propagating
to PE [15]. The initial health states in the
Markov model included ‘‘no VTE’’, ‘‘treated
DVT’’, ‘‘treated PE’’, ‘‘untreated VTE’’, and
‘‘death (absorbing state)’’, which would be
assigned for patients surviving the
decision-tree process. Patients surviving from a
PE and symptomatic DVT in the decision tree
would be assigned to the ‘‘treated PE’’ and
‘‘treated DVT’’ states, respectively. Patients
surviving from an asymptomatic, untreated
VTE would be assigned the ‘‘untreated VTE’’
state. Patients who had no VTE event or
incurred major bleeding without any sequelae
in the decision tree would be assigned the ‘‘no
VTE’’ state. Patients who incurred a fatal VTE or
bleeding would be assigned the ‘‘death’’ state.
In each 1-year cycle of the Markov process,
patients could incur a new or recurrent VTE.
The incidence of recurrent VTE was modeled as
a transitory event rather than a health state.
Patients in the ‘‘treated DVT’’ or the ‘‘untreated
VTE’’ states could incur a recurrent VTE or PTS.
Patients in the ‘‘treated PE’’ could incur a
recurrent VTE or CTEPH. Patients in the ‘‘no
VTE’’ state could incur an idiopathic VTE or
idiopathic PTS. The model assumed that a
recurrent or an idiopathic VTE would have the
same disease course profile and treatment
pattern as the tree shown in Fig. 1a, and
patients in the ‘‘PTS’’ or ‘‘CTEPH’’ state would
remain in their state until death. The all-cause
mortality risk was assumed to be the same for all
patients regardless of their health state.
Quality-adjusted life-years (QALYs) and costs
were discounted using an annual rate of 5% in
accordance with Chinese guidelines for
pharmacoeconomic evaluations [16].
Incremental cost-effectiveness ratios (ICERs)
presented as cost per QALY gained were
calculated to compare the two interventions,
e.g., A vs. B for thromboprophylaxis. When the
ICER was less than three times the per capita
gross domestic product (GDP) of China,
intervention A would be considered to be
cost-effective compared with intervention B
[17].
Clinical Inputs
In the decision tree model, the weighted
average efficacy and safety inputs of
enoxaparin for the acute phase model (Fig. 1a)
were estimated from pooled data derived from
two multinational clinical trials (the RECORD1
and ADVANCE3 study), which used the same
enoxaparin regimen (40 mg QD) as the control
strategy [18, 19]. On the basis of Chinese
clinical practices and the local setting, 40 mg
of enoxaparin per day is recommended for
thromboprophylaxis for patients receiving
major orthopedic surgery [5]. Table 1
summarizes the clinical data used in the
model. Because of the absence of head-to-head
treatment efficacy (VTE events) and major
bleeding data comparing rivaroxaban,
apixaban, and enoxaparin, a network
meta-analysis of randomized controlled trials
was used to estimate the relative risks of a VTE
event and major bleedings among patients
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Table 1 Clinical data used in the model
Parameters Base-case value Range tested References
Acute phase
Enoxaparin [18, 19]
Proximal DVT (%) 1.393 0.964–1.822
Distal DVT (%) 1.551 1.288–1.815
PE (%) 0.100 0.021–0.179
MB (%) 0.431 0.198–0.664
Hazard ratio of rivaroxaban versus enoxaparin [18, 19]a
Proximal DVT 0.022 0.0008–0.12
Distal DVT 0.480 0.22–0.98
PE 4.500 0.42–180
MB 3.400 0.76–23
Hazard ratio of apixaban versus enoxaparin [18, 19]a
Proximal DVT 0.340 0.13–0.75
Distal DVT 0.270 0.12–0.54
PE 0.590 0.083–4
MB 1.200 0.65–2.3
DVT is symptomatic of enoxaparin in 180 days (%) 14.530 11.624–17.436
DVT is symptomatic of rivaroxaban in 180 days (%) 14.550 11.640–17.460
DVT is symptomatic of apixaban in 180 days (%) 13.050 10.440–15.660
Long-term phase
Proximal DVT is symptomatic 0.400 0.243–0.557 [27–29]
Distal DVT is symptomatic 0.050 0.0304–0.0696 [27–29]
PE is symptomatic 0.320 0.195–0.445 [30]
Distal DVT propagates to the proximal vein 0.180 0.109–0.251 [31]
Proximal DVT propagates to PE 0.530 0.322–0.738 [15]
Case-fatality of MB 0.008 0.0049–0.0111 [8]
Case-fatality of PE during treatment 0.015 0.0091–0.0209 [32]
Case-fatality of PE asymptomatic 0.270 0.164–0.376 [33]
Case-fatality of PE immediately 0.220 0.134–0.306 [33]
Case-fatality of DVT (proximal or distal) during treatment 0.004 0.0024–0.0056 [32]
Annual probability of recurrent VTE
Year 1–2 0.081 0.049–0.113 [21]
Year 3–5 0.029 0.018–0.041 [22]
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treated with rivaroxaban or apixaban versus
enoxaparin [20].
In the Markov process, patients with a VTE
history might suffer a recurrent VTE and
develop post-PTS (in patients who suffered a
DVT) or CTEPH (in patients who suffered a PE).
The risk of recurrent VTE in the first and second
year was taken from an east Asian cohort study
[21], and the risks in subsequent years were
gathered from an 8-year follow-up observation
study [22]. The proportion of PE in recurrent
VTE was 30% in the Eastern population [23].
The probabilities of developing PTS were
obtained from a published epidemiological
study, which enrolled 528 consecutive patients
with a first episode of venography-confirmed
DVT [22]. The incidence of CTEPH after PE was
obtained from a prospective, long-term,
follow-up study of 223 consecutive patients
with acute PE [24]. Because of the absence of
long-term observational data, we assumed that
the risk of CTEPH would be considered only in
the first 2 years. The risks of idiopathic VTE and
PTS among patients without a history of VTE
were assumed to be the same as those of the
general population, and the estimates of these
risks were referenced to findings in the relevant
published literature [8]. The background
mortality in the Markov process was obtained
from the Chinese life expectancy tables of the
World Health Organization’s (WHO) member
states (2011) [25] and was assigned to all
patients regardless of health status [11].
When patients experienced recurrent or
idiopathic VTE during the Markov process,
they went through the disease course and
treatment pattern shown in the decision tree.
The relevant probabilities in the decision tree
Table 1 continued
Parameters Base-case value Range tested References
Annual probability of idiopathic VTE 0.002 0.0014–0.0032 [8]
Recurrent VTE is a PE 0.300 0.182–0.418 [23]
Idiopathic VTE is a PE 0.300 0.182–0.418 [15]
Recurrent DVT is a proximal DVT 0.660 0.401–0.919 [34]
Annual probability of PTS from treated DVT [22]
Year 1 0.180 0.109–0.251
Year 2 0.079 0.048–0.110
Year 3–5 0.023 0.014–0.032
Annual probability of PTS from untreated VTE 0.0012 0.0007–0.0017 [8]
Annual probability of idiopathic PTS 0.0008 0.0005–0.0011 [35]
Annual probability of CTEPH from treated PE [24]
Year 1 0.031 0.019–0.043
Year 2 0.007 0.0043–0.0097
DVT deep vein thrombosis, PE pulmonary embolism, VTE venous thromboembolism, CTEPH chronic thromboembolic
pulmonary hypertension, MB major bleeding, PTS post-thrombotic syndrome
a Risk ratio was estimated on the basis of the network meta-analysis
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were obtained from the relevant published
literature [15, 23, 26] and were assumed to be
the same for the three agents.
Costs and Resource Use
The analysis was conducted from the
perspective of the Chinese healthcare system.
In the analysis, the direct medical costs
included the retail prices of drugs,
management costs associated with VTE or
bleeding, treatment procedures and follow-up
visits, and the costs related to each permanent
condition (PTS or CTEPH care).
The purchase prices of rivaroxaban,
apixaban, and enoxaparin therapy were
obtained from an IMS China Hospital
Pharmaceutical Audit (CHPA) database in
2015; the cost of enoxaparin was that of
Clexane, which is the highest sold enoxaparin
in China. The mean duration (35 days) of
prophylaxis in the THR trials was assumed
[18, 19]. No administration cost was assumed
for rivaroxaban and apixaban, and the injection
cost of enoxaparin per unit was derived from
the reported Chinese analyses [36, 37]. The
direct costs of each complication are
summarized in Table 2. The event cost of
symptomatic DVT or PE considered both the
diagnosis and the hospitalization cost incurred
by the event, and the input value was reviewed
and confirmed by physicians in clinical practice
in China. Patients with symptomatic VTE after
discharge were assumed to switch to warfarin
therapy for 6 months, and the total costs of
anticoagulation were assumed to be the same as
those of patients with mechanical prosthesis
aortic valve replacement who received warfarin
anticoagulation treatment [38]. The resource
use in managing a major bleeding event was
based on a Chinese study analyzing the costs for
inpatient admissions due to major bleeding
events [39]. No cost was assumed for a minor
bleeding event because the cost incurred tends
to be negligible (on the basis of expert opinion).
The long-term resource use associated with PTS
and CTEPH included the diagnosis and
treatment costs in the first year and treatment
costs in the subsequent year [36, 37]. The
resource utilization for managing VTE in the
Markov process was assumed to be the same as
that in the acute phase of the model.
Utility Scores
QALYs were estimated by weighting life-years
by utilities. The utility scores of symptomatic
DVT, PE, PTS, MB, THR, and CTEPH were based
on estimates reported in previous publications
[8, 43–45] and are summarized in Table 2. The
utility score of 0.941 for the general population
was assumed for the post-operational period
until death or the end of the simulation [5]. The
same was assumed for patients with
asymptomatic VTE and no complications
[36, 37]. The duration of the disease course
was estimated to be 6 months for PE and
3 months for symptomatic DVT based on a
consensus of Chinese experts [5]. The utility
scores were estimated by considering the scores
for THR and other joint events such as DVT and
PE along the decision tree [46]. In the Markov
process, patients in the health states of ‘‘no
VTE’’, ‘‘untreated VTE’’, ‘‘treated PE’’, and
‘‘treated DVT’’ were assigned general
population utility scores [8, 36]. The utility
scores of transitory VTE events in the Markov
process were modeled on the basis of the
duration of treatment [8–10].
Sensitivity Analyses
To explore the model robustness, univariate and
probabilistic sensitivity analyses (PSA) were
472 Adv Ther (2017) 34:466–480
conducted. In the PSA, key model parameters
were simultaneously and randomly sampled
from the set parametric distributions to
produce 1000 estimates of the cost and QALY
for each pair of interventions of the comparison
of interest. A gamma distribution was selected
for the cost parameters and the beta distribution
for probability, proportion, and preference
value parameters. On the basis of the results of
the PSA, a cost-effectiveness acceptability curve
(CEAC) was presented. Univariate sensitivity
analyses were conducted for all parameters, and
the estimated range of each parameter was
either based on the reported or estimated 95%





Enoxaparin 40 mg per day (including administration
fee per unit)
8.94 4.48–8.94a 2015 IMS CHPA database
[36, 37]
Rivaroxaban 10 mg per day 13.30 6.65–13.30a 2015 IMS CHPA database
Apixaban 5 mg per day 14.63 7.32–14.63a 2015 IMS CHPA database
Diagnosis of PE per unit 112.07 84.05–140.09 [36]
Diagnosis of DVT per unit 68.50 51.37–85.62 [36]
Management of inpatient PE per event 1296.12 490.97–1964.27 [40]
Management of inpatient DVT per event 871.18 360.13–1030.74 [41]
Anticoagulation for 6 months after VTE discharge 96.25 72.19–120.31 [38]
Management of MB per event 716.11 687.44–744.78 [39]
CTEPH diagnosis per event 306.67 186.46–424.44 [36, 42]
CTEPH treatment per year 33,028.30 32,063.81–88,000 [42]
PTS–ﬁrst year 1323.03 804.4–1831.07 [37]
PTS–subsequent years 624.60 379.76–864.45 [37]
Utility values
Asymptomatic VTE/general population 0.941 0.75–1 [8]
Symptomatic DVT for 3 months 0.81 0.55–0.94 [43]
PE for 6 months 0.75 0.45–0.91 [43]
MB for 1 week 0.55 0.15–0.86 [43]
PTS 0.962 0.93–0.98 [8]
THR for 6 months 0.805 0.604–1 [44]
CTEPH 0.63 0.52–0.73 [45]
DVT deep vein thrombosis, PE pulmonary embolism, VTE venous thromboembolism, CTEPH chronic thromboembolic
pulmonary hypertension, MB major bleeding, PTS post-thrombotic syndrome, THR total hip replacement, CHPA China
Hospital Pharmaceutical Audit
a Half prices of enoxaparin and apixaban were used for the one-way sensitivity analysis
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confidence intervals in the referenced studies or
determined by assuming a 25% change in the
base-case value, except for the branded drugs
(apixaban and enoxaparin), whose prices were
assumed to be reduced by 50% because the
negotiations of Chinese national drug prices
always request that the prices of branded drugs
be sharply reduced (Table 2). Instead of the
incremental cost-effectiveness ratio for which
statistical inference is often difficult [47], the
incremental net-health benefit (INHB), a linear
transformation of incremental costs and
effectiveness, was utilized with the following
formula: INHB (k) = (lE-treatment - lE-control) 9 k
- (lC-treatment - lC-control)/k = DE - DC/k, where
lC and lE are the population’s average cost and
effectiveness of the treatment or control,
respectively [48], and k is three times the GDP
per capita of China in 2014 as
willingness-to-pay (WTP) threshold that was
generally recommended by the Chinese
guidelines for pharmacoeconomic evaluations
[16]. The model development and data analysis
were conducted using Microsoft Excel 2013
(Microsoft, Redmond, WA, USA).
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of




Compared with enoxaparin, 35 days of
prophylaxis with rivaroxaban and apixaban
increased the cost by US $151.56 and US
$178.70, respectively (Table 3). Rivaroxaban
resulted in 0.0064 fewer QALYs than
enoxaparin, and apixaban yielded 0.0025
QALYs more than enoxaparin. Therefore,
rivaroxaban was inferior to enoxaparin, and
the ICER of apixaban over enoxaparin was US
$71,244/QALY.
Sensitivity Analysis
In the comparison between rivaroxaban and
enoxaparin, the most sensitive parameters
included the risk ratio of PE and the cost of
rivaroxaban (Fig. 2); changes in these factors
might yield substantial changes in the net
health benefits in Chinese patients with THR.
Compared with that of enoxaparin, the cost of
apixaban was the most sensitive parameter. If
the cost of apixaban decreased by 50%, the gain
in net health benefits would be higher than
zero. Other parameters, such as the cost of
enoxaparin and the risk ratio of PE, had a
moderate or weak effect on the model outcome.
In general, these analyses suggest that the
model outcomes were robust.
Table 3 Base-case results: rivaroxaban and apixaban versus enoxaparin
Strategies Enoxaparin Rivaroxaban Apixaban
Cost (US $) 359.94 511.50 538.64
QALY 4.4890 4.4826 4.4915
ICER ($/QALY)a – Dominated 71,244
QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio
a Compared with enoxaparin
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The results of the PSA of THR are shown in
the cost-effectiveness acceptability curves
(Fig. 3); the proportions of the simulations in
which rivaroxaban, apixaban, and enoxaparin
were cost-effective were 0.00%, 0.00%, and
100.00%, respectively, at a cost-effectiveness
threshold of US $22,140 (three times GDP per
capita of China in 2014).
Fig. 2 Univariate sensitivity analyses for rivaroxaban versus enoxaparin (a) and apixaban versus enoxaparin (b). DVT deep
vein thrombosis, PE pulmonary embolism, VTE venous thromboembolism, HR hazard ratio
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DISCUSSION
The current study examined the
cost-effectiveness of three potentially
competing thromboprophylactic agents,
including two new oral anticoagulants
(rivaroxaban and apixaban) and one low
molecular weight heparin (enoxaparin), which
is recommended in current Chinese clinical
practice. By combing the decision tree used for
acute events (180 days) and the Markov model
used for long-term complications (5 years), we
found that the extrapolated results were
inconsistent with the projections reported by
Sullivan et al. and others [7–13]. The results of
this study were based on the current
understanding of the natural history of VTE
and the best available clinical evidence, which
provides reliable information for
decision-making in reimbursement listing and
the allocation of healthcare resources.
Our analysis suggests that patients receiving
enoxaparin for prophylaxis would gain more
health benefits and incur lower overall costs for
up to 5 years in comparison with rivaroxaban in
a cohort population of Chinese patients after
THR. Thrombophylaxis with apixaban in place
of enoxaparin would generate more QALYs but
a higher total cost and result in an ICER of US
$71,244/QALY, which is far higher than the
threshold of US $22,140 (three times GDP per
capita of China in 2014). Therefore, enoxaparin
is a cost-effective and dominant strategy in
patients undergoing THR surgery in China. The
potential reason for the increased QALYs gained
by enoxaparin versus rivaroxaban might be the
fewer events of PE that further lead to a smaller
incidence of CTEPH and mortality. Our study
highlights that the presence of these clinical
complications are the key QALY drivers.
Overall, lower complication costs were
estimated for patients who received
enoxaparin, which has also been shown to
have lower risks for such complications. The
results should be carefully explained because of
the small QALY differences and their associated
uncertainties. A small adjustment of the key
parameters might result in a great change of the
ICER of rivaroxaban and apixaban versus
enoxaparin.
Our study findings that rivaroxaban and
apixaban were not cost-effective in
comparison with enoxaparin were inconsistent
with the conclusions reported in previous
studies [11, 12, 37]. One plausible explanation
for this discrepancy is that unlike the previous
studies that have included one local Chinese
economic evaluation comparing apixaban and
enoxaparin, our model considered and included
CTEPH after a PE event as one long-term
complication, which was not included as a
Markov health state in other studies [11, 14].
The prognosis and quality of life of CTEPH
patients are poor, and the 3-year survival rate
has been reported to be as low as 40% in
Fig. 3 Acceptability curves regarding the cost-effectiveness
of rivaroxaban, apixaban, and enoxaparin. QALY
quality-adjusted life-year
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patients with a mean pulmonary arterial
pressure greater than 30 mmHg [49].
Furthermore, the cost of managing CTEPH was
expected to be nearly €36,768 per year, as
shown in a study analyzing the data of six
European countries [26]. The disease burden
related to CTEPH is also high in China [42].
Owing to this non-negligible cost, the effect of
CTPEH could not be, and was not, ignored in
this study. The second reason is that the time
horizon of the chronic phase in our analysis was
5 years, which might underestimate the benefits
of new oral anticoagulants by reducing the risks
of DVT because the PTS caused by DVT would
affect the health for a long time as other studies
had done [8, 10]. The third explanation for
differences between this and previous studies is
the higher cost of new oral anticoagulants and
lower costs of enoxaparin and managing VTE
events in China in comparison with those in
developed countries [7–13], thus explaining the
relatively lower offset of the costs of new oral
anticoagulants, including both rivaroxaban and
apixaban, in China.
In the comparison between rivaroxaban and
enoxaparin, the results of base-case analysis
were insensitive to adjustments in key
parameters, except for the purchase price of
rivaroxaban. This evidence further indicated
that the benefit of enoxaparin in reducing the
risk of PE and its complications had a
considerable effect on the model outcomes.
Therefore, enoxaparin might improve
outcomes at a lower total cost for
thromboprophylaxis in THR patients at high
risk of PE, such as those with a previous PE [24].
The results of univariate analysis for apixaban
against enoxaparin show the robustness of the
ICER to the changes in input estimates except
for the purchase price of apixaban.
This study also had several limitations. First,
because the lack of head-to-head treatment
results for these three strategies, the efficacy
and safety data of the prophylactic agents were
derived from different randomized controlled
treatment results. Tominimize the potential bias
and uncertainty in the outcomes, we usedwidely
accepted robust techniques to estimate the event
rate and tested the effects by using sensitivity
analyses. Second, the current analysis did not
weigh the risks of stroke and myocardial
infarction caused by embolisms and secondary
events such as death.However, findings from the
trials suggested that there were no statistically
significant differences in cardiovascular
outcomes among rivaroxaban, apixaban, and
enoxaparin [18, 19]. Third, our study did not
address quality-of-life impairment attributed to
the daily injection of enoxaparin. On the basis of
the opinions of experts, there is no evidence
showing that short-term treatment with
enoxaparin affects the quality of life of THR
patients. Fourth, a number of assumptions that
were made in the model to extrapolate the
results, such as the long-term risks of VTE, PTS,
and CTEPH, might have introduced additional
uncertainties in our analysis [14]. We attempted
to conduct an extensive sensitivity analysis to
test the effects of these potential uncertainties on
the cost-effectiveness results. Finally, as a result
of the absence of the explicit WTP threshold in
China, the current analysis used the three times
the GDP per capita of China in 2014 as the WTP
threshold, which might be varied by depending
on several factors. However, the uncertainties in
these parameters could be further reduced with
the availability of long-term follow-up clinical
data for these events.
CONCLUSION
To our knowledge, this is the first economic
evaluation study conducted in China to assess
the cost-effectiveness of VTE prophylaxis with
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rivaroxaban and apixaban versus enoxaparin in
Chinese patients after THR and in which all
possible known long-term complications were
considered. Our study indicates that enoxaparin
thromboprophylaxis in Chinese patients after
THR is still likely to be cost-effective.
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